Skip to content
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Home
Meetings Archive
Browse By Category
Browse By Keyword
Search
Search
2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Search by...
All
Authors and Affiliations
Title
Abstract Number
Keyword
Category
All
Clinical Vignettes
Innovations
Research
Sub-Category
(Optional)
Select Sub-Category...
Adult
Communication
Consultative Medicine
Education
Finalist
Geriatrics
Other
Outcomes Research
Patient Safety
Pediatric
Pediatrics
Perioperative
Quality Improvement
Technology in Hospital Medicine
Transitions of Care
Translating Research into Practice
Uncategorized
Value in Hospital Medicine
Winners
Session Type
Select Session Type...
Oral Presentations
Plenary Presentations
Meeting
All Meetings
SHM Converge 2024
SHM Converge 2023
SHM Converge 2022
SHM Converge 2021
Hospital Medicine 2020, Virtual Competition
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Hospital Medicine 2015, March 29-April 1, National Harbor, Md.
Hospital Medicine 2014, March 24-27, Las Vegas, Nev.
Hospital Medicine 2013, May 16-19, National Harbor, Md.
Hospital Medicine 2012, April 1-4, San Diego, Calif.
Hospital Medicine 2011, May 10-13, Dallas, Texas.
Hospital Medicine 2010, April 8-11, Washington, D.C.
Hospital Medicine 2009, May 14-17, Chicago, Ill.
Hospital Medicine 2008, April 3-5, San Diego, Calif.
Hospital Medicine 2007, May 23-25, Dallas, Texas
Hospital Medicine 2006, May 3-5, Washington, D.C.
Search Results for
Direct Oral Anticoagulant
Abstract Number: 20
THROMBOTIC RISK WITH WARFARIN, DABIGATRAN, OR ENOXAPARIN AFTER DOAC FAILURE
SHM Converge 2024
Background: The direct oral anticoagulants (DOACs) apixaban and rivaroxaban are increasingly prescribed due to convenient oral formulation without the need for routine laboratory monitoring and are now commonly regarded as first line anticoagulants in most cases of venous thromboembolism (VTE). However, the optimal choice of subsequent anticoagulant in instances of first line DOAC failure is […]
Abstract Number: 395
WARFARIN TO DIRECT ORAL ANTICOAGULANTS (DOACS) TRANSITION IN ELIGIBLE PATIENTS
SHM Converge 2024
Background: Direct acting oral anticoagulants (DOACs) have been approved for conditions such as non-valvular atrial fibrillation and venous thromboembolism. High quality randomized controlled trials have demonstrated the safety and efficacy of DOACs as compared to warfarin with exceptions in specific patient populations (such as those with mechanical heart valves). DOACs are more convenient and generally […]
Page load link
Go to Top